View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 12, 2021

Pfizer reports real-world evidence for Covid-19 vaccine in Israel

The Israel Ministry of Health (MOH), Pfizer and BioNTech have reported real-world evidence showing significantly reduced incidence rates of Covid-19 in fully vaccinated people.

The Israel Ministry of Health (MOH), Pfizer and BioNTech have reported real-world evidence showing significantly reduced incidence rates of Covid-19 in fully vaccinated people.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The Pfizer-BioNTech Covid-19 Vaccine (BNT162b2) is based on the latter’s mRNA technology and authorised for emergency use in over 60 countries.

The latest data build upon and reinforce earlier evidence from the MOH showing the vaccine’s effectiveness in preventing symptomatic SARS-CoV-2 infections, Covid-19 cases, hospitalisations, severe and critical hospitalisations and deaths.

According to the latest information, protection is more robust two weeks after the second vaccine dose. Also, the vaccine showed at least 97% effectiveness in preventing symptomatic disease, severe and critical disease and death.

In addition, the analysis showed a 94% vaccine effectiveness against asymptomatic disease.

Pfizer noted that this real-world evidence could be important to all nations as they advance their inoculation campaigns a year after the World Health Organization (WHO) declared Covid-19 a pandemic.

MOH director professor Yeheskel Levy said: “Incidence rates in the fully vaccinated population have massively dropped compared to the unvaccinated population, showing a marked decline in hospitalised cases due to Covid-19.

“This clearly demonstrates the power of the Covid-19 vaccine to fight this virus and encourages us to continue even more intensively with our vaccination campaign.”

The findings were derived from de-identified aggregate Israel MOH surveillance data obtained between 17 January and 6 March.

During this time, the Pfizer-BioNTech vaccine was the only vaccine in the country and the highly infectious B.1.1.7 variant of SARS-CoV-2 (the UK variant) was the dominant strain.

Pfizer Vaccines senior vice-president and chief medical officer Luis Jodar said: “The findings, which suggest that the vaccine may also provide protection against asymptomatic SARS-CoV-2 infections, are particularly meaningful as we look to disrupt the spread of the virus around the globe.”

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology